19SMCV00189

1 2 3 4 5 6	Philip Heller (State Bar No. 113938) ph@fhllplaw.com Jerold Fagelbaum (State Bar No. 92584) jfagelbaum@fhllplaw.com FAGELBAUM & HELLER LLP 2029 Century Park East, Suite 3550 Los Angeles, California 90067-3021 Telephone: (310) 286-7666 Facsimile: (310) 286-7086 Atternaya for Plaintiff	
7	Attorneys for Plaintiff James Parker	
8	SUPERIOR COURT	OF CALIFORNIA
9	COUNTY OF L	LOS ANGELES
10		~
11	James Parker	Case No.:
12	Plaintiff,	VERIFIED COMPLAINT FOR DAMAGES FOR:
13	VS.	1) Breach Of Express Contract
14	MM Enterprises USA, LLC, a limited	(Demotion);
15	liability company, and DOES 1 through 25, inclusive,	2) Breach Of The Implied Covenant Of Good Faith And Fair Dealing;
16	Defendants.	3) Breach of Express Contract (Termination Without Cause); and
17 18		4) Wrongful Termination In Violation Of Public Policy
19		DEMAND FOR JURY TRIAL
20	Plaintiff James Parker alleges:	
21	<i>J'ACCUSE</i> ¹	
22	1. The allegations set forth in this	Complaint present a compelling indictment of
23	certain members of senior management at Defe	endant MM Enterprises USA LLC. Contrary to
24	company issued statements that its Chief Fi	nancial Officer, Plaintiff James Parker, had
25	resigned, Mr. Parker had informed the compar	ny that, as a result of its breach of the written
26		
27 28	¹ The title of an open letter that Emile Zola wrote to on January 13, 1898 by the newspaper <i>L'Aurore</i> co More recently, denoting a public denunciation espe	ondemning the imprisonment of Alfred Dreyfus.

employment agreement it had with Mr. Parker, the pervasive and intolerable working conditions to which Mr. Parker was exposed, and forcing Mr. Parker to choose between complying with his fiduciary duty to the company and its shareholders or turning a blind eye and a deaf ear to improper and unlawful behavior, he had been constructively and wrongfully terminated without cause and in violation of public policy.

2. As detailed more fully below, even before the ink was dry on Plaintiff's 6 7 employment agreement, MM Enterprises was in breach and the nature and scope of the breach 8 only expanded over the coming months. With his authority and responsibilities being steadily 9 stripped away, Plaintiff was confronted with an environment replete with racial, homophobic 10 and misogynistic epithets and slurs, drug and alcohol abuse, personal humiliation occasioned by the words and deeds of the CEO and President of the company, profligate spending by both 12 the CEO and President, their indifference to management's fiduciary duty to the company and 13 its shareholders, and their disdain for compliance with the law in general as well as the laws 14 regulating publicly traded companion in the cannabis industry. Then in an ill-conceived 15 scheme intended to "shoot the messenger," rather than reform their ways, the CEO and 16 President initiated a disguised search for a new CFO behind Plaintiff's back. When Plaintiff 17 discovered Defendant's scheme and confronted the CEO and President, they resorted to 18 manufacturing a false "insubordination" claim and invoking self-serving disciplinary 19 procedures to create a pretextual paper trial which would culminate in a fabricated and 20 unjustified termination for cause and resulting loss of Plaintiff's contract benefits. Under these 21 circumstances, Plaintiff's departure from the company was far from voluntary, but rather, was 22 compelled in the face of unreasonable, continuing and substantial personal financial and legal 23 risk if he stayed.

I.

INTRODUCTORY ALLEGATIONS

3. Defendant MM Enterprises USA, LLC ("MM Enterprises") is, and at all times mentioned herein was, a limited liability company, organized and existing under the laws of

28

24

25

26

27

1

2

3

4

5

the State of Delaware with its principal place of business in Los Angeles County, California.
Plaintiff is informed and believes and upon that basis alleges that MM Enterprises is managed
by a sole manager, MM Can USA, Inc., a California corporation ("MM Can") and that MM
Can and MM Enterprises (*the* operational entity) are both wholly owned subsidiaries of
Medmen Enterprises, Inc., a British Columbia company whose stock is publicly traded on the
Canadian Securities Exchange.
4. Defendants DOES 1 through 25, inclusive, were at all times relevant herein employees.

4. Defendants DOES 1 through 25, inclusive, were at all times relevant herein employees, agents, and/or members of the Board of Directors of Defendant MM Enterprises or its affiliated companies. Plaintiff is ignorant of the true names and capacities of Defendants sued herein as DOES 1 through 25, inclusive, and therefore sues these defendants by such fictitious names. Plaintiff will pray leave of court to amend this complaint to allege the true names and capacities when ascertained. Plaintiff is informed and believes and thereon alleges that each of the fictitiously named defendants is responsible in some manner for the occurrences herein alleged, and that Plaintiff's damages as herein alleged were proximity caused by those defendants.

5. Plaintiff is informed and believes and thereon alleges that each of the defendants herein was at all times relevant to this action, the agent and employee of each of the remaining defendants, and in doing the things hereunder alleged, was acting within the course and scope of this agency or employment. Plaintiff is further informed and believes and thereon alleges that each of the defendants herein gave consent to, ratified, and authorized the acts alleged herein to each of the remaining defendants.

II.

ALLEGATIONS COMMON TO ALL CAUSES OF ACTION

6. Adam Bierman is the Chief Executive Officer and Andrew Modlin is the President of MM Enterprises. Together they started the primary businesses that were restructured into MM Enterprises in a reverse takeover transaction in early 2018. Selfproclaimed visionary entrepreneurs and "the ultimate disruptors," they focused upon what they

28

27

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

COMPLAINT FOR DAMAGES

believed were the tremendous business opportunities in the growing legalization of marijuana under state law, while downplaying the risks associated with the cultivation, sale and use of cannabis which remains illegal under federal law pursuant to the U.S. Controlled Substance Act of 1970 ("CSA"). According to MM Enterprises' public disclosures, if prosecuted by the Department of Justice, pursuant to the CSA, MM Enterprises could face seizure of its cash and other assets used to support or derived from its cannabis subdivisions, and its officers, employees, directors, managers, and investors could face charges of ancillary criminal violations of the CSA for aiding and abetting and conspiring to violate the CSA. Employment in the cannabis industry carries with it other problems as well. Employees of MM Enterprises, including Plaintiff, have had brokerage and bank accounts shut down, and insurance applications denied. Due to his employment by MM Enterprises, Plaintiff, in particular, no longer is eligible to qualify for a U.S. Government Top Secret security clearance, a credential Plaintiff previously held for eight years.

7. While prior Federal administrations have taken a more lenient view eschewing prosecutions of state regulated cannabis companies, the current Federal administration is viewed as more hostile. It remains uncertain how active prosecutions will be against companies who are nonetheless complaint with state law.

8. Against this risky backdrop, CEO Beirman and President Modlin asked Plaintiff to become MM Enterprises' first Chief Financial Officer. At the time, Plaintiff was the Chief Operation Officer of Treehouse Capital, the parent entity to the Medmen organization's previous Private Equity ventures. Plaintiff was a seasoned executive with extensive, high level experience in strategies overhaul, business planning and forecasting. He had held multiple C-Suite and senior level positions in private equity, consulting, investment management and banking. He also had earned an MBA from the USC Marshall School of Business and a B.A. from Rice University.

9. In February 2018, Plaintiff entered into a written employment agreement with
MM Enterprises which at the time was exclusively privately held. The agreement sought to

28

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

4 COMPLAINT FOR DAMAGES strike a balance between accepting the risks associated with any new business and the anticipated financial reward if the business was successful. (That agreement is *not* at issue in this action.)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

10. Confronted with the MM Enterprise inability to raise sufficient capital, punitive banking regulations, and legal challenges facing a cannabis company in the United States, Plaintiff was the genesis of the idea to qualify MM Enterprises into a fully rolled-up entity for the Canadian Securities Exchange. While MM Enterprises would remain the operational subsidiary, its indirect parent company, MM Enterprises, Inc., would become a publicly traded entity (*i.e.* "going public"). In preparation of taking MM Enterprises' indirect parent public and the enhanced regulatory scrutiny and fiduciary duties which would be owed to public investors, key members of MM Enterprises' senior management (including CEO Bierman, President Modlin, Chief Strategy Officer Chris Ganan, General Counsel Lisa Sergi Trager and Plaintiff) all entered into new similar, although not identical, employment agreements with MM Enterprises. The agreements provided each of them the *authority* necessary to perform their respective duties and obligations, and the *security* to exercise that authority to safeguard the company as well as to protect the interests of the investing public. (As organized, MM Enterprises' Senior Management also held identical titles in its parent company MedMen Enterprises, Inc.)

11. Reflective of the critical role a CFO occupies in general and, in the case of a soon to be publicly traded company in particular, Plaintiff's operative agreement provided in relevant part as follows:

1. <u>Position and Term.</u> *** Your title and position as Chief Financial Officer will not change during the term of this Agreement and you will not be demoted. This Agreement will be in full force and effect for four (4) years form the date of your countersignatures below. At the end of that four (4) year period, this Agreement will automatically renew for an additional three (3) year period under financial terms that will be targeted to increase by fifty (50%) percent from the terms currently provided herein, subject to approval by the Chief Executive Officer and the Board of Directors of the Company ("the Board")

2. General Duties and Responsibilities. As Chief Financial Officer, you will report to the Chief Executive Officer. The Chief Financial Officer is charged with the financial, accounting, tax, and the financial aspects of the risk management operations of the company. This includes the development of a financial and operational strategy, metrics tied to that strategy, and the ongoing development and monitoring of control systems designed to preserve company assets and report accurate financial results. As part of your responsibilities, will you monitor and direct the implementation of strategic business plans, develop financial and tax strategies, manage the capital request and budgeting processes, develop performance measures that support the company's strategic direction, participate in key decisions as a member of the executive management team, manage the accounting, investor relations, tax, and treasury departments, oversee the financial operations of subsidiary companies and any foreign operations, manage any third parties to which accounting or finance functions have been outsourced, and oversee the issuance of financial information and reports. These are examples of your duties and responsibilities and

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

other tasks may be assigned to you from time to time by the Company's Chief Executive Officer where he/she deems necessary or desirable.

(Letter Agreement at 1)

(A true and correct copy of Plaintiff's Letter Agreement re Employment with MM Enterprises, dated May 18, 2018, is attached hereto as Exhibit A and hereby incorporated by reference herein as though set forth in full.)

12. As a result of the tireless efforts of Plaintiff and others, on May 29, 2018, MedMen Enterprises, Inc. was listed on the Canadian Securities Exchange and the economic details of Plaintiff's compensation package was detailed in the publicly-available listing Prospectus filed with the listing application.

13. While management in a private company may have to answer to its investors, who may be more willing to allow greater latitude to nurture an entrepreneurial spirit, management in a public company is ultimately answerable to its public shareholders. CEO Bierman and President Modlin have failed to appreciate this distinction and have engaged in a course of conduct which recklessly jeopardizes the operations of the company, its ability to raise additional capital and the value of shareholders' interests.

14. MM Enterprises' parent going public was an enormous boon to CEO Bierman and President Modlin (to the tune of hundreds of millions of dollars in direct and indirect equity value) along with other initial investors in MM Enterprises. However, while more than willing to accept the benefits of now heading a publicly traded company, neither CEO Bierman, nor President Modlin, was willing to accept the accompanying responsibilities. They continued to conduct themselves as if it was their personal company, rather than as custodians of the public's trust. This included numerous instances of questionable use of public funds including, but not limited to, suspicious payments consistent with manipulation of Defendant's stock price, projects targeting third parties believed to have "wronged" the founders personally, profligate spending both personal and company-related, and a general

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

dismissiveness of behavioral requirements expected of executives of a publicly traded corporation.

15. Oblivious to the critical role a Chief Financial Officer has both to the company and its shareholders, CEO Bierman and President Modlin wanted to continue operating MM Enterprises as they saw fit. They viewed Mr. Parker's allegiance to his duties to *the company* and his fiduciary duty to *its shareholders* as an impediment to, and incompatible with, their unfettered conduct. Moreover, having achieved the paramount goal of becoming a publicly traded company, CEO Bierman and President Modlin viewed Mr. Parker as expendable and (encouraged by MedMen Enterprises, Inc. Chairman of the Board Ben Rose) that the time had come to "upgrade" to a "NASDAQ quality" CFO (although ostensibly one who would not have all the benefits provided to Plaintiff). If this was the objective, Defendant could have disclosed its intent to Plaintiff and bought out his contract. Instead, Defendant concluded it would try to force out Plaintiff and avoid paying him what he was due pursuant to their Letter Agreement.

16. To achieve indirectly what they could not achieve directly (*i.e.* termination for cause), CEO Bierman and President Modlin engaged in a rolling demotion in breach of Plaintiff's contract. In so doing, CEO Bierman and President Modlin further undercut Plaintiff's duty and authority to look out for the interests of the company and its shareholders by, among other things, identifying and attempting to rectify CEO Bierman and President Modlin's excessive and unnecessary spending, and engaging in transactions and other conduct which subordinated the interests of shareholders.

17. Without limitation, although expressly precluded from doing so, CEO Bierman and President Modlin interfered with and diminished Plaintiff's responsibilities with respect to securities law compliance, Investor Relations, Purchasing, Corporate Development, Capital Markets, expense controls, financial operations and processes, and corporate compensation. His authority was deliberately undercut. The Corporate Communications Director openly stated, "I don't have to listen to James, I only answer to [CEO] Adam." Others felt no need to

28

27

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

seek Plaintiff's approval for projects or spending, or the necessity to adopt and adhere to the policies Plaintiff established to ensure compliance with MM Enterprises' fiduciary responsibility. Instead, Plaintiff was confronted with what he viewed as a cult of personality. CEO Bierman and President Modlin demanded and received whatever they wanted, whether or not it was in the best interests of the Company. Plaintiff was labelled as angry, old and overly conservative because he had to constantly tell the CEO and President what they were doing was not allowed and that Defendant was not their personal piggy bank. After paying each of the founders (who already own combined more than 20% of a \$2 Billion market cap entity) \$1.5 Million in salary a year, Plaintiff was ordered to spend several millions of company dollars on such items as 24-hour armed Executive Protection (security) for the CEO, President, and their families, high-tech safe rooms and security systems for their new houses, personal drivers, private jets (often with friends and family along for the ride), luxury hotels, specialorder pearl white Escalades for the CEO (and another car for his family), a custom \$160,000 Tesla SUV demanded by the President, tens of thousands of dollars apiece on multiple extravagant custom conference room tables, and placing CEO Bierman's personal therapist and marriage counselor on staff fulltime as a "performance improvement expert" at a pay rate in excess of \$300,000 a year. Plaintiff as CFO had reduced authority in the company and employees knew it. Employees openly dismissed his policies and procedures because they were in favored groups (such as Operations and Marketing run by President Modlin, or Communications and Corporate Development run by CEO Bierman) or had long-standing special relationships with President Modlin and CEO Bierman. For example, Plaintiff was required to approve a \$1200 sushi dinner for President Modlin and his Chief of Staff because Plaintiff had to tell her she was not getting a raise. (However, the Chief of Staff then received a 100% raise a month later to \$250,000 a year approved solely by the President.) Against that backdrop, Plaintiff was tasked with managing it all. To that end, the CEO and President would contact Plaintiff morning, noon and night directing spending matters and incredulously asking "why can't we pay our bills on time?" and relaying that the Chairman of the Board wanted to know "why the company's burn rate was so high?" or, demanding to know why management fee payouts from the Private Equity funds (where Plaintiff is not employed) were lower than expected,

18. Moreover, rather than participate in key decisions as a member of the executive management team as contractually mandated, Plaintiff was marginalized with respect to communications with the Finance Team, excluded completely from the company's predicate roadshow for the purchase of Pharmacann (although the Pharmacann CFO was included) and Pharmacann's Finance and Accounting teams were then reflected in a public organizational chart as reporting to *both* President Modlin *and* Plaintiff, rather than exclusively to Plaintiff. (This was the only such group assigned a founder "babysitter", and a clear violation of the responsibilities laid out in Plaintiff's contract ("*i.e. to* oversee the financial operations of subsidiary companies.")

19. About the same time, CEO Bierman and President Modlin took direct action to surreptitiously attack and undercut Plaintiff's title and position as Chief Financial Officer. With an eye towards replacing Plaintiff as CFO, Plaintiff is informed and believes and upon that basis alleges that CEO Bierman and President Modlin consulted with attorneys at MM Enterprises, outside counsel and with counsel from its largest investor to assess the enforceability of Plaintiff's Letter Agreement. Convinced of its validity and the high burden associated with establishing "termination for cause," CEO Bierman and President Modlin adopted a different strategy.

20. CEO Bierman and President Modlin accelerated their campaign to deny Plaintiff the benefits to which he was entitled under the terms of his contract (*i.e.* by coercing Plaintiff to move "up or out", ostensibly without triggering the company's severance obligations under paragraph 6 of their Letter Agreement.) (Ex. A.)

25 21. Unbeknownst to Plaintiff at the time, Plaintiff is informed and believes and
26 upon that basis alleges that on or about October 8, 2018 CEO Bierman miscoded an invoice,
27 circumvented normal invoice process and went behind Plaintiff's back to pay \$50,000 to an

executive search firm (specializing in searching for financial executives) which had been retained on or about September 25, 2018 under cover of a "Management Assessment" project. When Plaintiff discovered the charge, he was told it was for a "confidential search" for a new Chief Information Officer, that had been "approved by Adam and Andrew." Given that Plaintiff already had been instructed to search for and communicate with data scientist specialists as introduced by Chairman of the Board Ben Rose, there was no logical reason for the CIO search to have been confidential, let alone kept confidential from Plaintiff, or outside of Plaintiff's established contract review and spending processes. CEO Bierman eventually admitted to Plaintiff that the leading CIO candidate was already known to the company, thereby making the engagement of a \$50,000 retained search recruiter unnecessary and merely a subterfuge to hide the search for a new CFO. (Plaintiff was humiliated again, this time before his Accounts Payable team, members of which clearly saw what was taking place having researched the invoice, discovered the inconsistency in the invoice and the service provider, and brought it to Plaintiff's attention.)

15 When Plaintiff became aware of these events, he brought it to the attention of 22. 16 CEO Bierman at an October 27, 2018 meeting with the CEO who, after first denying it had 17 anything to do with replacing Plaintiff as CFO, then "suggested" that Plaintiff renegotiate his 18 agreement for a more "strategic role" in the Company, and "let some other geek handle the audit." (CEO Bierman's proposal was that Plaintiff became "Vice-President of Strategy." 20 Given that Chris Ganan already was Chief Strategy Officer, the proposed title created by CEO Bierman for Plaintiff was a not a C-suite level position such as his then current position as 22 Chief Financial Officer and would have relegated Plaintiff to a position of sidelined 23 irrelevance, a demotion that violates the second line of Plaintiff's Employment Agreement.) 24 Plaintiff indicated he was not interested in another position. CEO Bierman continued to insist even telling Plaintiff (falsely) that General Counsel Lisa Sergi Trager had agreed to a demotion 26 to Senior V.P./Legal reporting to a new General Counsel and implying that Plaintiff should similarly play ball. Nevertheless, shortly thereafter, MedMen Enterprises, Inc. Chairman of

28

27

25

1

2

3

4

5

6

7

8

9

10

11

12

13

14

19

the Board, Ben Rose, met with Plaintiff and announced as a *fait accompli* "I understand you are moving into a more strategic role and I am very supportive". Subsequently, when Plaintiff protested to CEO Bierman that Plaintiff had not agreed to any such move and that CEO Bierman should not have represented to Mr. Rose that Plaintiff had done so, CEO Bierman replied "Fuck Ben Rose. He someone's bitch. Why do you care about him? The only thing that matters is our supervoting shares." (The CEO and President own *all* the supervoting shares, which shares provided them with enhanced voting power.)

23. At this point, it was President Modlin's turn. In response to Plaintiff's objections to the material breach of his agreement with MM Enterprises, President Modlin claimed in a clearly pretextual and retaliatory gesture, in an email dated November 1, 2018, that Plaintiff had granted unauthorized "stay bonuses" to key employees in his department (which, had been initiated nearly four months, earlier and, according to Plaintiff, were critical to MM's Enterprises' then recently completed and successful audit and earnings call; arguably a historical first, given MM Enterprises unique structure, industry, and cross-border nature.) The following day, President Modlin elevated the charge into an existential threat and imposed disciplinary remedies:

James,

As you know, I did not approve the payment of "stay bonuses." As you also know, you did not have the authority to unilaterally authorize stay bonuses. As I explained to you, the concept of paying stay bonuses runs contrary to MedMen's culture. In addition, your insubordination in unilaterally authorizing the stay bonuses constitutes misconduct in the performance of your duties that is not subject to cure within the meaning of the Letter Agreement RE: Employment. Nevertheless, MedMen is not presently electing to terminate your employment with Cause. In addition, you have engaged in other serious neglect in the performance of your duties and you have willfully and repeatedly failed and refused to perform your duties. We

28

27

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

will be providing you with a more detailed description of your performance deficiencies shortly as well as a plan for curing those deficiencies. Let me state unequivocally that, as opposed to the allegations made by your attorney, MedMen has not changed your title and it has not demoted you. We have proposed that you consider a change in position, but we have neither indicated that we intend to unilaterally implement any such change. We look forward to a constructive discussion with you concerning the improvement of your employment performance so that we can move forward and continue to create value for our employees and shareholders.

Andrew

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

(Email 11/2/18 at 8:42 a.m.)

24. Later the same day Plaintiff (who by contract reported directly to the CEO, not the President, and who had already agreed not to grant similar bonuses in the future to avoid any repetition of the issue) replied to President Modlin's clumsy attempt to change the focus from MM's Enterprises' breach of contract to a discussion over fabricated and suddenly materializing "performance deficiencies:"

Andrew,

The timing and substance of your email leads to only one conclusion pretext. Your self-serving mischaracterization of "insubordination," and claim of neglect and failure to perform my duties, are both unjustified and unsubstantiated.

This is not the time or place to debate with you the events leading up to your provocative email of today, but as part of your proposed constructive discussion about my performance be prepared to discuss the problematic conduct and behavior displayed by both Adam and you inconsistent with the terms of my Letter Agreement and how that poses an actual threat to creating value to our employees and shareholders.

It's time for you to stop your charade and address the real issue at hand. This is not about my performance (I am ready, willing and able to do, and am doing, my job). It is about your misguided attempt to walk away from your contractual obligations. That discussion can be had now and there is no need to wait while you scramble to draft a list of fabricated performance deficiencies. Since you already have seen fit to engage outside counsel and refer to our Letter Agreement, further discussions related to our respective duties, obligations and performance should be handled through our respective counsel. Of course, that issue aside, our regular business communications may proceed uninterrupted.

Regards,

James

(Email 11/2/18 at 12:30 p.m.)

25. Refusing to engage in represented negotiations between MM Enterprises and Plaintiff, President Modlin insisted upon subjecting Plaintiff to a sham "plan to improve your performance" disciplinary protocol to place Plaintiff on a path to fail and ultimately termination for cause:

James,

Your response is misguided. I intend to have a comprehensive discussion with you about what MedMen, as your employer, expects of your performance on a going forward basis. I am also happy to discuss with you any issues that you perceive with the performance of any other MedMen employee, myself included. We value your opinion. We are by no means "scrambling." Rather, we are taking the time to thoughtfully memorialize the myriad well documented deficiencies in your performance so that both you and MedMen can understand what is expected of you in your very well compensated position. Given the amount of your base salary, the annual

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

bonus available to you, and the value of the equity grants given to you, MedMen has every right to expect you to perform your job duties admirably. We will communicate the deficiencies that we perceive in your performance directly to you, in writing as is required by your employment agreement, and then we will discuss with you directly a plan to improve your performance. You are an employee of MedMen and, as such, MedMen will manage your employment performance with you directly. It is unreasonable to ask that your supervisors communicate employment performance feedback for one of their key executives through that executive's attorney. The employer employee relationship simply does not work that way.

We will provide you with the letter outlining your performance deficiencies early next week. I am looking forward to getting you on the right track to fulfill your employment obligations to MedMen. In the meantime, if you would like to discuss this matter, please contact me any time.

Andrew

(Email 11/2/18 at 1:27 p.m.)

26. At that point, it was apparent that not only was MM Enterprises unwilling to negotiate in good faith with respect to its contractual obligations, but also, it had taken active steps to manufacture a scenario in which Plaintiff could not succeed and thereby would provide MM Enterprises with an excuse to terminate him for cause. Not only would Plaintiff be so hamstrung so as to be unable to perform his full range of responsibilities to the company and its shareholders, but so long as he stayed he would become a "dead man walking," vulnerable to a fabricated and negative performance evaluation and, while tasked with his fiduciary duty, a scapegoat for any future problem which might arise. In this regard, Defendant had a pattern of terminating people after key deadlines or discrete periods of usefulness had passed. Some examples included the former Head of Capital Markets (terminated after the Reverse Takeover

COMPLAINT FOR DAMAGES raised \$100,000,000 at a \$1.65 Billion valuation, then a record for a U.S.-based cannabis company); the former Chief Marketing Officer (after helping to carry the company through the historic launch of recreational cannabis sales in California, a recruiter was engaged to find his replacement, who then requested his termination); the former Chief Operating Officer (who, deemed expendable after the Reno cultivation factory was opened, was terminated as soon as the company had identified a high-profile replacement COO); and the Managing Director for Real Estate Investment (who was terminated after supervising multiple construction projects simultaneously in coordination with recreational legalization of cannabis effective January 1, 2018.) While none of these former employees had the same contractual protections of Plaintiff, Defendant's use, abuse and discard practices was a common denominator.

27. Over time, working at MM Enterprises evolved from miserable to intolerable. By way of example, CEO Bierman and President Modlin's persistent and pervasive misconduct during the term of Mr. Parker's written agreement was offensive and at times unlawful: Mr. Parker was forced to tolerate being ridiculed by CEO Bierman and President Modlin for the way Plaintiff dressed (not hip enough to satisfy the Founders' millennial culture); being called "fat and sloppy"; being called a "pussy-bitch;" having his office diminished in size; assigned to a shared a parking space with his executive assistant while less senior VP's and Administrative Assistants had their own exclusive spots; subjected to hearing CEO Bierman's racially inappropriate reference to Los Angeles City Councilman Herb Wesson as a "midget negro" and the CEO's characterizations of cannabis social equity programs as "reparations"; CEO Bierman's references to a representative of the Drug Policy Alliance as a "fat, black lesbian;" CEO Bierman's and President Modlin referring to women in conflict with them as "cunts" and those with different ideas or perspectives as being "retarded;" CEO Bierman's public description (in front of the SVP, Corporate Communications) of an employee who was late for work being "up in his hotel room fisting his boyfriend" and instructing Plaintiff to "go up to his room, take his fist out of his boyfriend's

ass, and tell him to get to work;" being subjected to the CEO coming to the office and Defendant's events high and the President getting belligerently drunk at Defendant sponsored events; the President and CEO ignoring reported cocaine use at a company event by senior staff, and ultimately, Plaintiff having to deal with the all of the resulting cultural fallout at the company; relegated to using his personal American Express card to fund company purchases ranging from \$150,000-\$250,000 *a week* because CEO Bierman and President Modlin, and Defendant could not obtain credit cards with high enough limits since MM Enterprises was in the cannabis industry (reimbursement for which had become more problematic in light of recent events); being subjected to last-minute questioning about Plaintiff's handling of the audit and earnings process (going so far as the Chairman of the Board dismissively questioning the necessity of Plaintiff's – the Chief Financial Officer of a public company - physical attendance at Defendant's first earnings call, despite the Chairman's lack of prior involvement up to that point); and receiving no support from CEO Bierman, President Modlin, and General Counsel Sergi, as Plaintiff pushed a historic (and successful) regulatory filing across the line.

28. Most problematic, however, was MM Enterprises' increasing interference with Plaintiff's fiduciary obligations to the company and its publicly trading shareholders (placing him at substantial personal financial and legal risk), including, among others,

a) ordering Plaintiff to wire hundreds of thousands of public dollars to a "consultant" in Canada to "buy up our stock when it is under attack" (Plaintiff repeatedly asked for the trading report and what exactly happened to the stock that was purchased, was provided nothing, and told simply this was the way things operated in Canada);

 b) ordering Plaintiff to fund third-party intelligence groups to "dig up dirt" on perceived corporate and personal enemies;

 ordering Plaintiff to pay prohibited success fees to unlicensed brokerdealers for various fundraising efforts, under the semblance of "consulting agreements";

1		
2	d)	the CEO and President refusing to retract a materially incorrect press
3		release regarding a real estate transaction until Plaintiff forced them
4		to do so by demanding that the correction be included in the annual
5		Management Discussion & Analysis subsequent event section;
6	e)	the CEO and President not being fully transparent about non-arm's
7		length deals with numerous related parties (including Pharmacann and
8		Captor Capital);
9	f)	the CEO and President failing to publicly disclose all Named
10		Executive Officers and other Material Officer compensation packages
11		(in violation of Canadian National Instrument Form 51-102 F6 which
12		requires that the compensation of the CEO, CFO and next three
13		highest paid executives be publicly disclosed);
14	g)	the CEO and President ordering the opening of a sham office in
15		Vancouver (while maintaining a primary, custom designed office in
16		Toronto) with the expressed intent of shifting the provincial regulator
17		away from Ontario to British Columbia (which is perceived to be
18		more permissive);
19	h)	ordering Plaintiff to pay for improvements to CEO Bierman and
20		President Modlin's personal homes under the guise of "Executive
21		Protection" without being provided a scope of work or attaining prior
22		approval before the work was complete, and without being provided
23		a comprehensive security policy after repeated requests (President
24		Modlin referred to the security policy, which provides numerous
25		lucrative benefits to the Founders, as "really just a tax document in
26		the end" and completely ignoring that the security policy was
27		designed for their protection, not for their personal convenience);
28		
		18 COMPLAINT FOR DAMAGES

 ordering Plaintiff to sign and execute what Plaintiff is informed and believes and upon that basis alleges were over-market contracts for deals and services with parties to maintain the personal relationships of Chief Strategy Officer Chris Ganan;

- j) compelling Plaintiff to make political contributions personally because Defendant had maxed out its legal donations and the CEO had promised additional donations to a candidate in Nevada and being required (prior to going public) to directly pay (with Defendant's funds) for a personal furniture purchase for the President, which Plaintiff is informed and believes and upon that basis alleges, was to offset a sizeable donation the President had made, but which could not be directly reimbursed by Defendant who had met its contribution limit;
- k) the CEO stating to Plaintiff that the CEO was falsifying his personal brokerage statement when applying for his home mortgage, with the assistance of the President, in order to qualify to purchase his home, ignoring the fact that if such behavior became a matter of public record it would cause untold damage to the business (as cannabis licenses often have "clean record" requirements, not to mention the public perception issues surrounding executives that feel free to commit bank fraud); and
- Plaintiff being confronted by the MedMen Enterprises, Inc. Chairman of the Board who insisted, despite an irrefutable conflict of interest, that his investment position in one of the private equity funds (which, in turn, is a major shareholder of the public company) be given preferential treatment to advance his own personal economic interests in direct, and fundamentally statutory, conflict with his fiduciary duty

1	to the public company's shareholders, but Plaintiff being deprived of
2	the authority to do anything about it.
3	In light of these and similar circumstances, on November 5, 2018 Defendant was advised that
4	Plaintiff was unable to continue as CFO without violating his duty to the company, and his
5	fiduciary duty to its indirect parent and its shareholders, because the CEO and President had
6	created an environment where Plaintiff was stripped of the authority required to manage
7	expenditures in a public company setting notwithstanding his supposed position. The CEO and
8	President had usurped and maintained effective control and sole authority over what was paid,
9	and when, regardless of the impact it may have had upon the Defendant and the threat to
10	shareholder value. When taken in the aggerate, these events were sufficiently coercive,
11	extraordinary and egregious to give rise to constructive discharge by MM Enterprises.
12	III.
13	FIRST CAUSE OF ACTION
14	(Breach Of Contract-Demotion)
15	(Against Defendant MM Enterprises)
16	29. Plaintiff incorporates by reference and realleges Paragraphs 1 through 28,
17	inclusive.
18	30. As previously set forth herein, on May 18, 2018 Plaintiff and Defendant MM
19	Enterprises entered into a written contract for employment. (Ex. A.)
20	31. Plaintiff has performed all conditions, covenants and promises required on his
21	part to be performed in accordance with the terms and conditions of the contract except as to
22	those as to which performance has been excused by Defendant's breach.
23	32. During the period of May 18, 2018 through November 5, 2018, Defendant
24	breached its contract with Plaintiff by failing to assign to Plaintiff all the responsibilities to
25	which he was entitled as Chief Financial officer pursuant to paragraph 2 of the contract and,
26	as to those responsibilities that were initially assigned, by subsequently re-assigning certain of
27	those responsibilities to others. (As initially structured, the Finance/Accounting, Capital
28	

Markets/IR, Legal, HR and Corporate Development group were all to report to Plaintiff. Over time, all but Finance and Accounting were reassigned to others: Legal to the General Counsel, HR to General Counsel and President; Corporate Development to the CEO, and IR to 4 Corporate Communications, and Pharmacann's Finance and Accounting team to the President.) Additionally, Plaintiff was assigned as reflected on Defendant's new organizational 6 chart to report to both the CEO and the President (and, in practice, only reporting to the President on a day-to-day basis), in direct violation of his contract (which provided he was to 8 report directly to the CEO). By limiting his responsibilities, Plaintiff was deprived of critical information necessary to fully discharge his remaining responsibilities and by requiring him 10 to report to both the CEO and President, his authority within the company was diminished. The loss of responsibility and authority within the company was a material breach of Plaintiff's 12 Letter Agreement and resulted in a demotion of Plaintiff (both in terms of reduction in stature 13 and authority within the company) notwithstanding that he retained the title and compensation 14 of CFO, and exposed Plaintiff to increased risk, both legal and financial, by limiting his ability 15 to fulfill Plaintiff's fiduciary duty to the company and the investing public. Moreover, 16 Defendant's decision to engage a CFO search firm and insistence that Plaintiff either move up 17 and re-negotiate his contract (with lesser benefits), or else be subjected to ever increasing 18 harassment and sham disciplinary proceedings to force him out, was a further material breach 19 of his contract the terms of which were intended to protect Plaintiff from such intimidation. 20 Defendant's actions have materially changed the terms and conditions of Plaintiff's employment contract and in so doing have breached the contract and excused Plaintiff from 22 further performance, while requiring Defendant to comply with all remaining financial terms 23 of the contract.

24 33. As a result of Defendant's breach of contract, Plaintiff has been damaged in an 25 amount in excess of this Court's jurisdictional minimum, the exact amount of which will be 26 subject to proof at trial. Plaintiff also has incurred reasonable attorney fees in attempting to 27 secure the benefits owed to him under his employment agreement.

28

21

1

2

3

5

7

9

11

21 COMPLAINT FOR DAMAGES SECOND CAUSE OF ACTION (Breach Of The Implied Covenant Of Good Faith And Fair Dealing) (Against Defendant MM Enterprise)

34. Plaintiff incorporates by reference and realleges Paragraphs 1 through 33, inclusive.

IV.

35. The employment contact referred to herein as Ex. A. contained an implied covenant of good faith and fair dealing, which obligated Defendant to perform the terms and conditions of the agreement fairly and in good faith and to refrain from doing any act that would prevent or impede Plaintiff from performing any or all of the conditions of the contract that he agreed to perform, or any act that would deprive Plaintiff of the benefits of the contract.

36. Prior to the roll-up that created the consolidated Medmen entity that would eventually be publicly listed, Plaintiff was offered and accepted the Chief Operating Officer role with the predecessor private equity funds. As the evolution of the organization proceeded, Defendant initially contracted with Plaintiff in an agreement, dated February 19, 2018, to become the Chief Financial Officer of what was going to be part of a publicly traded companya sign of Defendant's admiration of Plaintiff's skills and abilities. Defendant was so impressed with Plaintiff's performance including, but not limited to, his material role in conceiving the idea and helping to implement how the company could go public as well as facilitate the entity's first ever full third-party audit and comprehensive listing prospectus, that it offered to enter into a new contract with Plaintiff that included enhanced terms and benefits. That new agreement, the operative agreement at issue herein, was signed on May 18, 2018 shortly before MedMen Enterprises Inc., began publicly trading on May 25, 2018. However, after MedMen Enterprises Inc., went public, Plaintiff is informed and believes and on this basis alleges that Defendant concluded that Plaintiff was expendable and, with the urging of MedMen Enterprises, Inc.'s Chairman of the Board, Ben Rose, could and should be replaced by a

28

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

"NASDAQ level CFO", with "more juice and better connections" (but without the enhanced contract that had been provided to Plaintiff and other members of Senior Management). Plaintiff had been assured by CEO Bierman that Chairman of the Board Ben Rose had reviewed and approved all of the executive compensation packages but given Rose's overwhelmingly negative response shortly after the Reverse Takeover (and the subsequent negative publicity regarding similar but more lucrative packages provided to the CEO and President), it became apparent that assurance was false. To that end, Defendant embarked upon an underhanded and craven campaign to compel Plaintiff to change positions, forego the benefits to which he was entitled under his operative contract, and renegotiate for a reduced benefits contract, or move out, but without triggering the severance benefits contained in his contract.

37. As allowed in paragraph 27 above, Defendant's campaign included verbal ad *hominem* and personal attacks on Plaintiff. He was personally humiliated and disrespected by acts within the organization, included downsizing his office and assigning him to shared parking space while other executives and some subordinates had their own spaces. More substantively, the scope of his responsibilities was cut back so that Investor Relations no longer reported to him and he was given no input into the selection of a new third-party Investor Relations consulting firm; Purchasing was not required to report to him, yet he was tasked with the responsibility for having all bills paid on a timely basis; he was excluded from fund-raising and non-deal "road-shows" (notably the Pharamcann roadshow which as previously mentioned did include the Pharmcann CFO who did not have any public CFO experience); no longer kept abreast of fundraising efforts on a timely manner; excluded from participating in new acquisitions, including, but not limited to, the fundamental approval or structuring of said deals; and his role in participating in key decisions as a member of the executive management team was reduced. Plaintiff's ability to supervise and lead was compromised when subordinates learned that they could go around Plaintiff by aligning themselves with the CEO or President. Then, on or about September 25, 2018, Plaintiff is informed and believes and

upon that basis alleges that CEO Bierman initiated a formal search for a new CFO under the 2 guise of looking for Chief Information Officer. Only when confronted face to face by Plaintiff, 3 did CEO Bierman admit he wanted Plaintiff to take on a new role as "Vice President of 4 Strategy" pursuant to a *re-negotiated* (*i.e.* reduced benefits) contract. When Plaintiff objected, 5 President Modlin exploited a contrived issue over Plaintiff's issuance of "stay bonuses" (again, a modest \$30,000 split among six people to ensure the company met statutory deadlines) and 6 7 used it as a predicate for a claim of insubordination to initiate a "plan to improve your 8 performance" based upon "well-documented deficiencies." Actually, there were no such well-9 documented deficiencies (Plaintiff never had a formal negative performance review and his 10 personal file was "clean") and the plan to improve performance was nothing more than a roadmap for a trumped-up termination for cause charade.

38. In fact, Plaintiff had performed exemplarily all the duties and conditions of his employment agreement required up to that time and Defendant knew it. Defendant's plan ostensibly to improve performance based upon a trumped up "insubordination claim" was strictly retaliatory, a smokescreen designed to shift focus away from Defendant's own misconduct, and a contrived first step in a bad faith scheme to circumvent the termination for cause only requirement of his contract. Not only had President Modlin previously used "stay bonuses" to retain personnel who reported to him (contrary to his contention it was "against MedMen culture"), but on January 3, 2019, shortly after Mr. Parker's compelled departure, MedMen publicly filed a Material Change Report (regarding the then imminent PharmaCaan acquisition) which specifically detailed carving out \$4,000,000 for "stay bonuses" for key personnel (dwarfing the \$30,000 Mr. Parker had approved for comparable purposes in July 2018) and further exposed the false narrative that "stay bonuses" were contrary to Medmen culture.

25 39. As a proximate result of Defendant's breach of the implied covenant of good 26 faith and fair dealing, Plaintiff was denied the benefits to which he was entitled under his 27 contract, and has suffered, and continues to suffer, losses in earnings and other employment

28

1

11

12

13

14

15

16

17

18

19

20

21

22

23

benefits and severance benefits in an amount to be established at trial. As a further proximate 2 result of Defendant's breach of the implied covenant of good faith and fair dealing, Plaintiff 3 has incurred reasonable attorney fees in attempting to secure the benefits owed to him under 4 his employment agreement.

1

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

THIRD CAUSE OF ACTION (Breach Of Contract-Termination Without Cause) (Against Defendant MM Enterprises)

V.

40. Plaintiff incorporate by reference and realleges Paragraphs 1 through 39, inclusive.

41. Plaintiff's aforementioned employment agreement, dated May 18, 2018, also provided as relevant herein for a specific term of employment: four years, plus one automatic renewal for an additional three years; and also, provided that throughout the term Plaintiff would retain the title of CFO and not be demoted. (*Ex.* A at \P 1.)

Moreover, the employment agreement further provided that if Plaintiff 42. employment was terminated without "Cause," Plaintiff would be entitled to severance benefits:

6. Severance. In the event that your employment is terminated by the Company involuntarily without Cause:

a. The Company will provide you with a lump sum payment, to be paid on the first day of the month following the termination date, equivalent to three (3) times your then-current Base Salary for the year of the termination.

b. The Company will provide you with a lump sum payment, to be paid on the first day of the month following the termination date, equivalent to two (2) times your then-current Target Bonus Amount for the year of the termination.

1	c. Any unvested FV LTIPs (or AO LTIPs if granted in a subsequent
2	agreement) will immediately vest and convert into Common Units
3	on a one for one (1 to 1) basis on the day prior to the employment
4	termination date.
5	d. Any unvested stock options, restricted stock or other award will
6	immediately vest on the day prior to the employment termination
7	date.
8	e. The executive protection program referenced in Section 8.d,
9	below, will continue to apply, at the expense of the Company, for
10	six (6) months following your termination date. For this post-
11	severance benefit, the maximum amount of the benefit on an
12	annual basis will be U.S. Dollars (\$),
13	with no carryovers permitted between years (and no consequential
14	impact between or among years), and reimbursements will be paid
15	on a current basis (within ninety (90) days of the expense being
16	incurred) and, in any case, by the end of the year after the year in
17	which the expense in incurred. Notwithstanding Section 12 or any
18	other provision contained herein, this benefit cannot be liquidated
19	for cash or another benefit or substituted for other rights or
20	benefits.
21	f. The Company will provide you with a lump sum payment, to be
22	paid on the first day of the month following the termination date,
23	in the amount of Two Hundred and Fifty Thousand U.S. Dollars
24	(\$250,000).
25	For purposes of this Agreement, "Cause" shall mean, as determined by the
26	Board and unless otherwise provided in an applicable agreement with the
27	Company, (a) material violation of Company's policies, including the
28	
	26 COMPLAINT FOR DAMAGES

(disclosure or misuse of confidential information, or those set forth in 1 2 manuals or statements of policy issued by the Company; or (b) serious 3 neglect or misconduct in the performance of your duties for the Company or 4 willful or repeated failure or refusal to perform such duties. If Cause is 5 alleged, we will provide you with written notice of the Company's position, 6 and you will have ninety (90) days from your receipt of that notice to cure 7 the Cause allegation situation. The Board will review your cure efforts, and 8 the Board will review your cure efforts, and the Board will then provide you 9 with a written notice detailing its decision. 10 This Section 6 shall not apply in the event that you voluntarily terminate your 11 employment or if the Company terminates your employment for Cause. 12 (*Ex.* A. at 2-3) 13 43. Plaintiff have performed all conditions and covenants and promises required on 14 his part to be performed in accordance with the terms and conditions of the contract except as 15 to those as to which performance has been excused by Defendant's breach. 16 44. Based upon a combination of facts and circumstances previously alleged herein 17 in paragraph 28 above, including, but not limited to: a pervasive and ongoing campaign consisting of words and deeds 18 a) 19 conducted by MM Enterprises' CEO and President to embarrass, 20 ridicule and humiliate Plaintiff both on a personal and professional 21 level: 22 b) a steady stripping away of responsibility contrary to what had been 23 expressly provided in Plaintiff's employment contract; 24 c) the CEO demanding, in violation of Federal Election Campaign Laws, 25 that Plaintiff make a non-voluntary donation of \$10,000 to a candidate 26 the CEO had selected, and, separately, to obscure that Defendant's 27 funds were used to purchase furniture for the President which Plaintiff 28 27 COMPLAINT FOR DAMAGES

is informed and believes and upon that basis alleges offset a substantial financial donation the CEO had made to a candidate that could not be directly reimbursed by Defendant which already had reached its legal limits of its campaign donations;

d) subjecting Plaintiff to sham disciplinary procedures disguised to give cover for a plan to fabricate a "designed to fail plan" by which the Defendant could terminate Plaintiff ostensibly for alleged cause;

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

- e) forcing Plaintiff to select between the Hobson's Choice of either fulfilling his duty to the company and his fiduciary duty to its public shareholders or accede to the personal and out of control demands from the CEO and President, and their profligate spending of company funds for their own personal benefit while being accused of "insubordination" for actions made expressly for the public shareholder's protection;
- f) placing Plaintiff directly odds with the Chairman of the Board over the management of the "share overhang" and a closely-held share distribution plan, forcing Plaintiff to either call out the Chairman of the Board on his conflict of interest, or, given the lack of support from the CEO and President, to accept an outcome Plaintiff believed was biased against the shareholding public; and
- g) the CEO and President engaging in other improper activities which Plaintiff is informed and believes and upon that basis alleges placed Defendant in violation of Federal, State and Local Laws (including, for example, and not by way of limitation, 15 U.S.C. §78i; 18 U.S.C. §1014, Cal. Penal Code § 67 and §532 a; Cal. Bus. & Prof. Code §26080 and L.A. City Charter, Art. IV., Sec. 470).

Defendant either intentionally created or knowingly permitted working conditions that where so intolerable or aggravated at the time of Plaintiff's notice on November 5, 2018 that he would not be returning to work that a reasonable person in Plaintiff's position similarly would have been compelled to resign from a position in which he had been already constructively discharged.

45. As a result of Plaintiff's constructive discharge and termination without cause in breach of his employment agreement with Defendant, Plaintiff has suffered and continues to suffer losses in future earnings including salary (*Ex.* A at \P 3); bonuses (*Ex.* A at \P 4); equity grants (*Ex.* A at \P 5); other employment benefits (including but not limited to *Ex.* A at \P 8) and \P 10); his Severance Benefits (*Ex.* A at \P 6), unpaid salary due at the time of separation from Defendant, and a diminution in value of MedMen Enterprises, Inc. publicly traded stock held by Plaintiff, all to his damage in an amount to the established a trial. Plaintiff also has incurred reasonable attorney fees in attempting to secure the benefits owed to him under his employment agreement.

VI.

FOURTH CAUSE OF ACTION

(Wrongful Discharge In Violation of Public Policy)

(Against Defendant MM Enterprises And Does 1 through 25)

46. Plaintiff incorporates by reference and realleges Paragraphs 1 through 45, inclusive.

As Chief Financial Officer of MM Enterprises and its indirect publicly traded 47. parent company MedMen Enterprises, Inc., Plaintiff owed a fiduciary duty to, among others, MedMen Enterprises, Inc. and its shareholders. It was in that capacity that Plaintiff signed the financial statements upon which Plaintiff is informed and believes and upon that herein alleges that MedMen Enterprises, Inc. shareholders relied and based their investment decisions.

48. An officer's fiduciary duty is codified as public policy in California Corporations Code, § 309(a) (for corporations) and § 17704.09(f) (for limited liability

companies). Accordingly, officers owe fiduciary duties of loyalty and care to shareholders trading on a public exchange and any provision seeking to immunize officers from their betrayal of that trust are against public policy and unenforceable.

The general rules applicable to the duties of a corporate officer have been frequently stated. In the leading case of Guth v. Loft, Inc., 23 Del. CH. 255 [5 A. 2d 503, 510], these obligations were cogently described as follows: "Corporate officers and directors are not permitted to use their position of trust and confidence to further their private interests. While technically not trustees, they stand in a fiduciary relation to the corporation and its stockholders. A public policy, existing throughout the years, derived from a profound knowledge of human characteristics and motive, has established a rule that demands of a corporate officer or director, peremptorily and inexorably, the most scrupulous observance of his duty, not only affirmatively to protect the interests of the corporation committed to his charge, but also to refrain from doing anything that would work injury to the corporation, or to deprive it of profit or advantage which his skill and ability might properly bring to it, or to enable it to amend in the reasonable and lawful exercise of its powers."

> Bancroft Whitney Co. v. Glen (1966) 64 Cal. 2d 327, 245

49. While Plaintiff's contractually mandated responsibilities were being steadily eroded by the acts of Defendants, Plaintiff's statutory fiduciary duty of loyalty and care remained undiminished until such time as he resigned or was constructively terminated. The longer Plaintiff remained at work (albeit constrained by Defendant's conduct), the greater the risk to the public shareholders of MedMen Enterprise, Inc. who were unaware that Plaintiff no longer had the panoply of responsibilities and authority necessary to ensure that the conduct

28

27

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

of the officers and directors in MM Enterprises (in part as reflected in the consolidated financials prepared for MedMen Enterprises, Inc.) was in the best interests of the company (*i.e.* MM Enterprises and its publicly trader indirect parent MedMen Enterprises, Inc.). 50. As the risks to public shareholders grew, the legal and financial risk to Plaintiff

50. As the fisks to public shareholders grew, the legal and finalicial fisk to Plaintiff similarly increased. As his authority and responsibilities decreased, his potential for liability increased. Plaintiff was constructively discharged for refusing to ignore his fiduciary duty to the shareholders trading in MedMen Enterprise Inc., stock and insisting (often to no avail) that Defendant comply with applicable law (as alleged in paragraph 28 above). Rather than remedying the issue by complying with its contractual obligations, it was Defendant's intention to avoid its contractual obligations and thereby cripple Plaintiff's ability to comply with his fiduciary duty. Defendant's despicable conduct was designed to render Plaintiff's working conditions so intolerable and fraught with risk that any reasonable person in Plaintiff's position would feel compelled to resign from a position in which he had been already constructively discharged just as Plaintiff was forced to do. (Indicative of the nature and extent of Defendant's efforts *prior* to Plaintiff separating from the company, is the fact that a new CFO was sought out, identified, interviewed, reference and background checked, and vetted, he gave notice to his then current employer and was publicly announced on December 6, 2018 supposedly all within mere weeks of Plaintiff's separation.)

51. Defendant continued to mislead the investing public after Plaintiff's termination. Not only was no mention made of Plaintiff's termination made until a full eleven calendar days after the event (in direct violation of Canadian material event disclosure rules, which require almost immediate public announcement to prevent any unauthorized trading activity), but it was mischaracterized by Defendant as a "resignation". More brazenly, Defendant signed Plaintiff's name to a required monthly public progress report filing (Canadian Securities Exchange Form 7) using a digital signature kept on file on November 7th, 2018 – a full two (2) days after Plaintiff's termination. Additionally, Plaintiff is informed and believes and upon that basis alleges that, unknown at the time to Plaintiff, the Defendant agreed in principle to a

28

27

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1

"bought deal" financing (a fundraising where the underwriting bank takes on any price risk that occurs after the agreement) on November 8th, 2018 (three days after Plaintiff's termination) without first informing the underwriting syndicate of the material change in executive leadership. Plaintiff is further informed and believes and upon that basis alleges that Defendant renegotiated the aforementioned bought deal on November 16th at significantly less favorable terms (and causing an almost two-day trading halt). CEO Bierman subsequently stated to New Cannabis Ventures (arguably the most respected journalism site in the cannabis industry) that the "departure of the CFO was in no way related to the subsequent change in the financing." Instead, he deceptively contended that the unprecedented revision of the deal (a change which was demonstrably punitive to current shareholders including Plaintiff) was a result of market forces and Defendant's concern for its banking "partners". That statement was false. Rather than in response to "market forces," the renegotiation was indicative of the banking syndicate threatening to cancel the deal on the grounds of a material change (not previously disclosed by Defendant to the bank). Not content with deceiving the bank (and being caught and then having to renegotiate), CEO Bierman compounded his deception by then concealing from the investing public the real reason behind the retrade. When considered with previous actions, Defendant's further concealment demonstrates just how little respect Defendant and its executives had, and continue to have, for their fiduciary responsibility to the investing public or to the injurious impact it would have upon Plaintiff's reputation. Not surprisingly, after Defendant released its speculation-inducing comments concerning Plaintiff's "resignation" from the company, Plaintiff's bank summarily terminated its longstanding relationship with him.

52 Defendant's conduct was a substantial factor and proximate cause of Plaintiff's past and present harm, including but not limited to, general and special damages, humiliation, embarrassment and mental anguish, lost earnings, salary, bonuses, equity grants and other employment benefits, and severance benefits, and a diminution in value of MedMen Enterprises, Inc. publicly traded stock held by Plaintiff, all to his damages in an amount to be

established at trial. Plaintiff also has incurred reasonable attorney fees in attempting to secure the benefits owed to him under his employment agreement.

53. Defendant's acted with malice, fraud and oppression and in conscious disregard of Plaintiff's rights, financial interests and reputation justifying an award of punitive damages. Such conduct was done, without limitation, by Defendant's CEO and President with the intent that it would subject Plaintiff to personal humiliation, discomfort and risk to force Plaintiff "up or out" in an attempt to conceal and perpetuate Defendant's own wrongdoing at the expense of retail investors in MedMen Enterprises, Inc. stock and thereafter to intentionally mischaracterize Plaintiff's departure from the company to further Defendant's self-interest albeit to Plaintiff's detriment. As a consequence of such oppressive, malicious and despicable conduct by Defendant's managing agents subjecting Plaintiff to cruel and unjust hardship in conscious disregard of Plaintiff's rights, Plaintiff is entitled to an award of punitive damages in a sum to be shown according to proof at trial and in an amount appropriate to punish Defendant and deter others from engaging in similar misconduct.

VII.

PRAYER

WHEREFORE, Plaintiff prays for entry of judgment in favor of Plaintiff and against Defendants, and each of them, as follows:

F

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

For the First Cause of Action:

1. For damages for breach of contract according to proof, including lost earnings, bonuses, equity grants and other employee benefits, past and future;

2. For prejudgment interest on lost earnings, bonuses, equity grants and employee benefits at the prevailing legal rate from the date of the filing of the Complaint;

- 3. For post-judgment interest;
 - <u>33</u>

COMPLAINT FOR DAMAGES

1	4.	For reasonable attorney fees incurred by Plaintiff according to
2	contract;	
3	5.	For costs of suit incurred by Plaintiff; and
4	6.	For such other and further relief as the court deems proper.
5	For the S	econd Cause of Action:
6	7.	For damages for breach of contract according to proof,
7		including lost earnings, bonuses, equity grants, other employee
8		benefits, past and future;
9	8.	For prejudgment interest on lost earnings, bonuses, equity
10		grants, other employee benefits at the prevailing legal rate from
11		the date of the filing of the Complaint;
12	9.	For post-judgment interest;
13	10.	For reasonable attorney fees incurred by Plaintiff according to
14		contract;
15	11.	For costs of suit incurred by Plaintiff; and
16	12.	For such other and further relief as the court deems proper.
17	For the T	Third Cause of Action
18	13.	For damages for breach of contract according to proof,
19		including lost earnings, bonuses, equity grants (and
20		diminution in stock value) and other employee benefits, past
21		and future, and severance benefits;
22	14.	For prejudgment interest on lost earnings, bonuses, benefits,
23		equity grants and other employee benefits and severance
24		benefits, at the prevailing legal rate from the date of the filing
25		of the Complaint;
26	15.	For post-judgment interest;
27		
28		
		34
		COMPLAINT FOR DAMAGES

- 11			
1		16.	For reasonable attorney fees incurred by Plaintiff according to
2			contract;
3		17.	For costs of suit incurred by Plaintiff; and
+		18.	For such other and further relief as the court deems proper.
;		For the	Fourth Cause of Action
		19.	For compensatory damages according to proof, including
,			lost earnings, bonuses, equity grants (and diminution in
:			stock value), other employment benefits, past and future,
			and severance benefits and damages for humiliation,
			embarrassment and mental anguish;
		20.	For prejudgment interest on lost earnings, bonuses, equity
2			grants, other employee benefits, and severance benefits at the
3			prevailing legal rate from the date of filing of the Complaint;
-		21.	For post-judgment interest;
;		22.	For punitive damages in an amount appropriate to punish
5			Defendant and to deter others from engaging in similar
,			misconduct;
;		23.	For reasonable attorneys' fees incurred by Plaintiff according
,			to contract;
)		24.	For costs of suit incurred by Plaintiff; and
		25.	For such other and further relief as the court deems proper.
	Data h Ia	20	
↓	Dated: January 29, 2019 FACELBAUM & HELLER LLP		2019 FAGELBAUM & HELLER LLP
5			By: Class Algebrun
5			Jerold Fagelbaum / Attorneys for Plaintiff
7			James Parker
8			
			35 COMPLAINT FOR DAMAGES

VERIFICATION

I am a party to this action, and I have read the foregoing Complaint and know its contents. The matters stated in the Complaint are true based on my own knowledge, except as to those matters stated on information and belief, and as to those matters I believe them to be true.

I declare under penalty of perjury under the laws of the State of California that the foregoing is true and correct.

Executed on January 29, 2019 at Sherman Oaks, California.

James Parker

1		
1	DEMAND FOR JURY TRIAL	
2	Plaintiff hereby demands trial by jury on all issues triable of right by jury.	
3		
4	Dated: January 29, 2019	FAGELBAUM & HELLER LLP
5		0.12 11
6		By: Juli Allin
7		Jerold Fagelbaum Attorneys for Plaintiff
8		James Parker
9		
10		
11		
12		
13		
14		
15		
16		
17		
18 19		
20		
20		
22		
23		
24		
25		
26		
27		
28		
		37 DMPLAINT FOR DAMAGES
		JWILAINI FOR DAWAGES

EXHIBIT A

MM Enterprises USA, LLC 10115 Jefferson Blvd Culver City, CA 90232

May 18, 2018

via email: james@medmen.com James Parker, Chief Financial Officer MM Enterprises USA, LLC 13101 Morrison St. Sherman Oaks, CA 91423

Re: Letter Agreement Re: Employment

Dear James:

We are pleased to formally memorialize the terms of your position with MM Enterprises USA, LLC (the "Company") as the Chief Financial Officer, on the following terms and conditions, as set forth in this letter agreement (the "Agreement"):

- 1. <u>Position and Term.</u> Your position as Chief Financial Officer with the Company is already effective and this Agreement will formalize its terms in more detail. Your title and position as Chief Financial Officer will not change during the term of this Agreement and you will not be demoted. This Agreement will be in fall force and effect for four (4) years from the date of your countersignatures below. At the end of that four (4)-year period, this Agreement will automatically renew for an additional three (3)-year period under financial terms that will be targeted to increase by fifty (50%) percent from the terms currently provided herein, subject to approval by the Chief Executive Officer and the Board of Directors of the Company (the "Board").
- 2. General Duties and Responsibilities. As Chief Financial Officer, you will report to the Chief Executive Officer. The Chief Financial Officer is charged with the financial, accounting, tax, and the financial aspects of the nisk management operations of the company. This includes the development of a financial and operational strategy, metrics tied to that strategy, and the ongoing development and monitoring of control systems designed to preserve company assets and report accurate financial results. As part of your responsibilities, you will monitor and direct the implementation of strategic business plans, develop financial and tax strategies, manage the capital request and budgeting processes, develop performance measures that support the company's strategic direction, participate in key decisions as a member of the executive management team, manage the accounting, investor relations, tax, and treasury departments, oversee the financial operations of subsidiary companies and any foreign operations, manage any third parties to which accounting or finance functions have been outsourced, and oversee the issuance of financial information and reports. These are examples of your duties and responsibilities and other tasks may be assigned to you from time to time by the Company's Chief Executive Officer where he/she deems necessary or desirable.

- 3. <u>Base Salary, Expenses</u>. You will receive a base salary at an annual rate equal to Seven Hundred Fifty Thousand U.S. Dollars (\$750,000.00), payable in accordance with the Company's standard payroll policies and procedures (together with any increases, the "Base Salary"), which will not be subject to any reduction during the term of this Agreement. In the event that your employment is involuntarily terminated without Cause (as hereinafter defined) during the term of this Agreement, the Company will pay to you, in addition to any severance pay provided for herein, the Base Salary for the remainder of the year of the termination plus the Base Salary for any remaining years of the Agreement term, in one lump sum, on the first day of the month following your termination date. Your reasonable business expenses will be reimbursed according to the Company's then-current policies and procedures and no later than one (1) month after the expense incurred.
- 4. <u>Annual Bonus</u>. In addition to the Base Salary, you will be paid an annual bonus, prior to the March 15 following the year in which it is earned, at a target amount of One Hundred Fifty Percent (150%) of your then-current Base Salary for that year (the "Target Bonus Amount"). After considering the Target Bonus Amount level, the actual amount of your bonus (which may be higher or lower and may or may not include additional equity grants) will be determined after review by the Chief Executive Officer.
- 5. Equity Grants. At the execution of this Agreement and the implementation of the Company's RTO (but, in no event, later than May 17, 2018), you shall receive the following equity grants (the "Equity Grants"): (a) an outright grant of Common Units in the Company equal to Two Million Five Hundred Thousand (\$2,500,000) U.S. Dollars, and (b) a grant of Full Value LTIP ("FV LTIP") units equal to Seventeen Million Five Hundred Thousand (\$17,500,000.00) U.S. Dollars. The FV LTIP units will vest as follows: Two Million Five Hundred Thousand (\$2,500,000.00) U.S. Dollars will vest immediately, and the remaining Fifteen Million (\$15,000,000.00) will vest ratably, on a monthly basis, beginning on May 17, 2018 and concluding with all FV LTIPs fully vested on March 15, 2022. The Equity Grants are based on the value of the Company as set forth in the RTO concurrent financing. For the avoidance of doubt, such amount is One Billion Six Hundred Fifty Million (\$1,650,000,000.00) U.S. Dollars.
- 6. <u>Severance</u>. In the event that your employment is terminated by the Company involuntarily without Cause:
 - a. The Company will provide you with a lump sum payment, to be paid on the first day of the month following the termination date, equivalent to three (3) times your then-current Base Salary for the year of the termination.
 - b. The Company will provide you with a lump sum payment, to be paid on the first day of the month following the termination date, equivalent to two (2) times your then-current Target Bonus Amount for the year of the termination.

- c. Any unvested FV LTIPs (or AO LTIPs if granted in a subsequent agreement) will immediately vest and convert into Common Units on a one for one (1 to 1) basis on the day prior to the employment termination date.
- d. Any unvested stock options, restricted stock or other award will immediately vest on the day prior to the employment termination date.
- f. The Company will provide you with a lump sum payment, to be paid on the first day of the month following the termination date, in the amount of Two Hundred and Fifty Thousand U.S. Dollars (\$250,000).

For purposes of this Agreement, "Cause" shall mean, as determined by the Board and unless otherwise provided in an applicable agreement with the Company, (a) material violation of the Company's policies, including the disclosure or misuse of confidential information, or those set forth in manuals or statements of policy issued by the Company; or (b) serious neglect or misconduct in the performance of your duties for the Company or willful or repeated failure or refusal to perform such duties. If Cause is alleged, we will provide you with written notice of the Company's position, and you will have ninety (90) days from your receipt of that notice to cure the Cause allegation situation. The Board will review your cure efforts, and the Board will then provide you with a written notice detailing its decision.

This Section 6 shall not apply in the event that you voluntarily terminate your employment or if the Company terminates your employment for Cause.

7. <u>Public Trading, Public Listing, Etc.</u> In the event that the Company's equity shares are the subject of an initial public offering (or become publicly listed or are similarly traded publicly) on a major equity exchange market (either within or outside of the United States) and if the Company reaches an enterprise value of Two Billion U.S. Dollars (\$2,000,000,000) (regardless of the length of time the market capitalization is held), you will receive a cash payment of Two Million Five Hundred Thousand (\$2,500,000.00) U.S. Dollars no later than sixty (60) days after the conditions in this Section 7 are met. For the avoidance of doubt, if these events occur to a successor entity of the Company

(e.g., through a reverse acquisition or merger), this Section 7 shall also apply to that situation if no such payout has occurred in any related transaction pursuant to this Section 7.

- 8. <u>General Benefits, Specific Application, Mandatory Procedures</u>. You will be subject to all rules and policies applicable to employees of the Company at your level and in your position (which, as Chief Financial Officer, would be the senior executive level). You will be eligible to participate in all employee benefits plans and programs of the Company generally applicable to employees at your level and in accordance with their terms. Notwithstanding the above, the following will specifically apply to you regardless of the terms of the plans and programs:
 - a. <u>Vacation</u>. You will be entitled to an unlimited amount of vacation, paid time off, or its equivalent (unless prohibited by applicable law).
 - b. <u>Health Insurance. etc.</u> The Company will pay all of your premiums for your health insurance and related benefits (including coverage for your spouse and dependents), as well as your premiums or other costs for disability (your short-term disability benefit will provide at least your Base Salary for one (1) year if you are disabled, which will be in addition to your other normal benefits that will continue during any short-term disability), and life insurance benefits, and a benefit for executive financial counseling.
 - c. <u>Executive Insurance. Disputes.</u> The Company will maintain, and pay for, the standard insurance coverages for you that it maintains for its executives, including, but not limited to, liability protection in the form of directors and officers coverage, and, additionally, the Company will indemnify you against claims made against you related to your employment with the Company, including paying for your legal fees related to any such claim, even if the claim occurs after this Agreement has terminated. In such case, the provisions of Section 12 shall apply to the indemnification and payment of legal fees if required by the Code §409A rules.
 - d. <u>Executive Protection</u>. The Company will maintain a policy regarding mandatory executive protection (at the expense of the Company) in which you are required to participate. This policy has clear and objective definitions and a copy of this policy is attached hereto as Exhibit C.
- 9. <u>Termination</u>. Notwithstanding the contractual nature of your employment, both you and the Company agree to provide each other with ninety (90) days prior written notice of any intention to terminate your employment with the Company. Upon termination of your employment with the Company, this Agreement will also terminate except for the provisions of this Agreement that must survive for their force and effect.

- 10. <u>Death</u>. In the event of your death during the term of this Agreement, your estate shall receive the following from the Company:
 - a. A lump sum payment equivalent to the sum of X plus Y, where:

X = two (2) times your then-current salary; and

Y = the maximum annual bonus paid to you over the previous five (5) years pursuant to Section 4 of this Agreement,

which payment will be made to your then-current spouse on the first day of the second month after your death. An equivalent payment will be made on the one (1) year anniversary of that payment date.

- b. The remainder of your equity grants (that have not vested), which will then be fully vested when transferred to your spouse on the first day of the second month after your death.
- 11. Taxes, Gross-Ups, Make-Whole Payments. In the event that you are required to pay any taxes, other than standard federal, state, and/or local income taxes that generally constitute expected ordinary income or capital gains, the Company will reimburse you for any taxes, penalties, and interest that may be triggered by any other tax code provisions, including, but not limited to §409A of the Internal Revenue Code of 1986, as amended (the "Code"), taxes imposed for failed discrimination tests, excess parachute payments, income that is imputed to you resulting from a benefit or perquisite, or taxes imposed for any similar unanticipated tax issue such as those ancillary liabilities that may be incurred and that are related to the unanticipated tax issues. If the Company is required to provide you with a gross-up payment pursuant to this Section, it will also include in the gross-up amount consideration for the tax consequences of the gross-up amount in an amount to make you whole to the extent reasonably possible, and all such gross-up payments will be paid within thirty (30) days of the date that you remit any such payment to the taxing authority to extinguish the liability. Additionally, and subject to the remainder of this Agreement, in the event that the Company deems it no longer legally possible to provide a compensation amount, benefit, or perquisite that it is required to provide to you due to applicable law, insurance or vendor offerings, discrimination testing or similar legal, compliance, or availability considerations, it will provide you with a similar benefit or a cash amount equivalent to the value of the benefit that no longer is deemed permissible. In the event that such a reformatting or substitution of benefits results in noncompliance with the Code §409A rules, the new benefit or cash will be restructured to comply with the Code §409A rules to the extent possible, and to the extent not possible, the gross-up provisions provided herein will apply to make you economically whole as if there were compliance. Notwithstanding anything to the contrary contained herein, if Code §409A requires any payment to be delayed due to you constituting a "key employee" under the Code §409A rules, then such payment will be delayed for six (6) months (unless a different time period is then applicable for "key employees" under the Code §409A, in which case that required time period will apply). In that case, the delay of any such payment will end and the payment will be made on (or begin on) the first day of the

seventh month after the employment termination date in the same form (e.g., a lump sum) that it would otherwise have been made previously.

- 12. Dispute Resolution. Notwithstanding any other provision herein referencing legal fees, in the event that any dispute arises related to this Agreement, including if the dispute involves the Company, all of your legal fees will be paid by the Company regardless of the outcome of the dispute for your lifetime. In that case, the maximum amount of the benefit on an annual basis will be Five Hundred Thousand U.S. Dollars (\$500,000.00), with no carryovers permitted between years (and no consequential impact between or among years), and reimbursements will be paid on a current basis (within ninety (90) days of the expense being incurred) and, in any case, by the end of the year after the year in which the expense is incurred. Notwithstanding Section 11 or any other provision contained herein, this benefit cannot be liquidated for cash or another benefit or substituted for other rights or benefits.
- 13. <u>Exhibits</u>. Please note that the Exhibits to this Agreement are incorporated by reference herein and are part of this Agreement.

We look forward to your continued service according to this Agreement, and if you have any questions, please contact me.

Sincerely. MM Enterprises USA, LLC By: LOFIZED SIGNATORY Its:

James 2018

Exhibit A

to Letter Agreement (Confidentiality and Non-Disparagement Provisions)

A. Confidential Information.

1. Definition. During the course of your employment with the Company, you may receive confidential information of, and/or be in the possession of confidential information from, the Company, and/or its parents, subsidiaries, and any affiliated entities (collectively, "Affiliates"), as well as confidential information pertaining to the Company's clients or customers. Confidential information includes, but is not limited to, customer or client lists, services provided to such customers or clients, sources and leads for obtaining new business, vendors or suppliers, trade secrets, images, slogans, logos, designs, sketches, mockups, samples, computer software, operations, systems, services, financial affairs of the Company and/or its Affiliates, forms, contracts, agreements, literature, inventions, original works of authorship, copyrights, patents, trademarks, and any and all information and know-how, or other items designed, developed or written by, for, with, or on behalf of the Company and/or its Affiliates (whether or not such information constitutes "Work Product," as defined below), now or in the future (hereinafter. "Confidential Information"). Confidential Information shall not include concepts, ideas, discoveries, or techniques intrinsic to your knowledge or experience (to the extent that those concepts, ideas, discoveries, or techniques are unrelated to the Company and its proprietary information), or information which is or which comes into the public domain through no fault of yours.

2. <u>Exclusive Property</u>. All Confidential Information is, and at all times shall remain, the exclusive property of the Company. You recognize and acknowledge that Confidential Information is valuable, special and unique to the business of the Company and its Affiliates, and that access to and knowledge thereof is essential to the performance of your duties to the Company. During the time that you are an employee of the Company, and at all times thereafter, you will keep secret and will not use or disclose any Confidential Information to any person or entity, in any fashion or for any purpose whatsoever, except at the request of or with prior written consent of the Company (or as may be required by applicable law).

B. Non-Disparagement.

<u>Non-Disparagement/No Speaking with the Media</u>. Both during your employment with the Company and at all times thereafter, you agree that, except as required by applicable law or compelled by process of law, you will not, nor will you permit anyone acting on your behalf to (i) make any derogatory, disparaging, or critical statement about the Company, or (ii) without the permission of the CEO/President of the Company (or the Board where it deems necessary or desirable), communicate, directly or indirectly, with the press or other media (including, but not limited to, any electronic media) concerning the past or present employees or business of the Company.

Exhibit B

to Letter Agreement (General Provisions)

1. <u>No Waiver</u>. No failure or delay by you or the Company in exercising any right under this Agreement will operate as a waiver thereof or preclude any other or further exercise thereof or the exercise of any other rights.

2. <u>No Oral Modification</u>. This Agreement may not be changed or modified except by a written agreement that has been signed by the Company's CEO/President or approved by the Board.

3. <u>Reformation and Severability</u>. The provisions of this Agreement shall be enforced to the fullest extent possible, but if any court of competent jurisdiction or arbitration panel determinates that any provision of this Agreement is unenforceable, that provision shall not impair the remaining provisions of this Agreement. In addition, if any provision is held to be unenforceable because of the scope, duration or area of its applicability, the court or tribunal making such determination shall have the power to modify such scope, duration and/or area, and such provision shall then be applicable in such modified form and every other provision of this Agreement shall remain in full force and effect.

4. <u>Representation</u>. You acknowledge that you have had the opportunity to seek legal and tax counsel prior to entering into this Agreement, and that any legal or tax counsel representing the Company does not also represent you.

5. <u>Tax Matters</u>. All amounts of compensation paid to you shall be paid subject to applicable taxes, withholdings, and deductions, including compliance, where necessary, for issuances of equity interests in the Company and Code §409A, each where applicable.

6. <u>Applicable Law</u>. This Agreement shall be interpreted in accordance with the laws of the State of California, where appropriate, unless preempted by federal law.

7. <u>Entire Agreement and Assignment</u>. This Agreement, including the Exhibits, represents the entire agreement between you and the Company regarding your employment with the Company and supersedes any and all previous and contemporaneous agreements and representations, written or oral. The Company may assign this Agreement to any successor or assign. Notwithstanding the above, this Agreement shall be binding on any successor to the Company by purchase or otherwise.

8. <u>Interpretation</u>. If a provision of this Agreement requires interpretation, the parties agree that no presumption against one party shall apply by reason of the rule of construction that a document is to be construed more strictly against the party who prepared the document.

9. <u>Return of Property</u>. Upon termination of this Agreement, you will immediately return and surrender to the Company originals and all copies of all records, notes, memoranda,

information, documents, and other property created or obtained by you as a result of, or in the course of, or in connection with, your employment with the Company hereunder, including Confidential Information.

10. <u>Notice</u>. Unless one party provides a new address to the other, any notice required under this Agreement shall be written and executed by the sender. Notice shall be sufficient if personally delivered or mailed (or electronically mailed) as follows:

If to James Parker, then to: James Parker, CFO 13101 Morrison St. Sherman Oaks, CA 91423

If to the Company, then to:

MM Enterprises USA, LLC c/o______ 10115 Jefferson Blvd Culver City, CA 90232

11. <u>Counterparts</u>. This Agreement (and its Exhibits) may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one agreement. The headings of the various sections of this Agreement have been inserted for reference only and shall not be deemed to be a part of this Agreement.

Exhibit C to Letter Agreement (Executive Protection Policy)

45619980v3

•

۰**۰**

•

.